Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Gasherbrum Bio
South San Francisco, California, United Statesir.structuretx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Gasherbrum Bio is developing orally available small molecule GLP‑1 receptor agonists. Its lead candidate, aleniglipron (GSBR‑1290), has reached Phase 2 clinical trials for obesity and type 2 diabetes. Preclinical work is ongoing in Parkinson’s disease. Clinical results to date have not been published in detail, but multiple Phase 2 studies are active or recently completed.
- Therapeutic areas
- OphthalmologyEndocrinologyNeurology
- Modalities
- Small moleculeGlucagon-like peptide 1 receptor agonist (GLP-1RA)
- Industry
- Biotech
02
Partnerships
Structure Therapeutics
Beyond the preview
Go deeper on Gasherbrum Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gasherbrum Bio.